Biotech Values

[jq1234]

"We are going to make a data-driven decision," he said, explaining that Halozyme is weighing whether to license its technology to makers of existing insulins, partner with makers of diabetes drugs who do not currently have an insulin product, market its own product with insulin pumps or all of the above.

http://www.reuters.com/article/2011/06/26/us-diabetes-halozyme-idUSTRE75P1YM20110626